Key Facts
Latest information about our company.
Global Business
Updated November 2021
Chief Executive Officer:
Headquarters:
Princeton, New Jersey, USA
Business:
Biopharmaceuticals
Web Address:
NYSE Listing:
BMY
Full-year Revenue (2020):
$42.5B
R&D Investment (2020):
$11.1 billion which included the discovery and development of new medicines for patients
Principal Locations:
Local Business
Updated June 2023
General Manager:
Elaine Phillips
Head Office:
Montreal, Quebec, Canada
Address:
2344 Alfred-Nobel,
Suite 300
Saint-Laurent, QC
H4S 0A4
CANADA
Suite 300
Saint-Laurent, QC
H4S 0A4
CANADA
Areas of Focus:
Oncology
Hematology
Immunology
Cardiovascular disease
Hematology
Immunology
Cardiovascular disease
Key products :
ABECMATM (idecabtagene vicleucel)
ELIQUIS® (apixaban)
ONUREG ® (azacitidine tablets)
OPDIVO® (nivolumab)
ORENCIA® (abatacept)
POMALYST® (pomalidomide)
REBLOZYL® (luspatercept)
REVLIMID® (lenalidomide)
YERVOY® (ipilimumab)
ZEPOSIA® (ozanimod)
ELIQUIS® (apixaban)
ONUREG ® (azacitidine tablets)
OPDIVO® (nivolumab)
ORENCIA® (abatacept)
POMALYST® (pomalidomide)
REBLOZYL® (luspatercept)
REVLIMID® (lenalidomide)
YERVOY® (ipilimumab)
ZEPOSIA® (ozanimod)
COVID-19: Our Response and Path Forward
Contact:
1 800 267-1088